| Sep 23 |
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
|
| Sep 19 |
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
|
| Sep 13 |
Cidara axes 30% of staff to focus on flu prevention drug
|
| Sep 12 |
Cidara cutting 30% of workforce to focus on CD388 for influenza
|
| Sep 12 |
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
|
| Sep 5 |
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 19 |
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
|
| Aug 13 |
Cidara Therapeutics GAAP EPS of -$20.65, revenue of $0.3M
|
| Aug 13 |
Cidara Therapeutics: Q2 Earnings Snapshot
|
| Aug 13 |
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
